Supplementary Figure S3 from Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies
Year: 2024
Type: supplementary-materials
Abstract: Supplemental Figure 3. Serum cytokine levels in subjects receiving SYNB1891
Language: English
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4402803265